<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravenous PSA medications for adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravenous PSA medications for adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intravenous PSA medications for adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="15%"></colgroup> <colgroup width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Initial dose</td> <td class="subtitle1">Onset (minutes)</td> <td class="subtitle1">Duration (minutes)</td> <td class="subtitle1">Repeat dose (as necessary)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Propofol</td> <td>0.5 to <span class="nowrap_whitespace">1 mg/kg</span></td> <td>0.5</td> <td>5</td> <td>0.25 to <span class="nowrap_whitespace">0.5 mg/kg</span> every 1 to <span class="nowrap_whitespace">3 minutes</span></td> <td> <ul> <li>Sedative and amnestic. No analgesia.</li> <li>Rapid onset and neurological recovery.</li> <li>Useful in older adults without major comorbidities; reduce dose by â‰¥20% (maximum initial bolus: <span class="nowrap_whitespace">0.5 mg/kg)</span> and administer slowly (eg, over 3 to <span class="nowrap_whitespace">5 minutes).</span></li> <li>Respiratory depression, hypotension, and injection site pain may occur.</li> <li>Contains egg lecithin, soybean oil (potential allergens; refer to UpToDate discussion of perioperative anaphylaxis).</li> </ul> </td> </tr> <tr> <td>Etomidate</td> <td>0.1 to <span class="nowrap_whitespace">0.15 mg/kg</span></td> <td>5 to <span class="nowrap_whitespace">15 <strong>seconds</strong></span></td> <td>5 to 15</td> <td><span class="nowrap_whitespace">0.05 mg/kg</span> every 3 to <span class="nowrap_whitespace">5 minutes</span></td> <td> <ul> <li>Sedative. No analgesia.</li> <li>Generally maintains hemodynamic stability. Useful for patients at risk of hypotension.</li> <li>In older adults or patients with impaired kidney or liver function, use doses at lower end of range.</li> <li>Myoclonus, respiratory depression, injection site pain, and nausea/vomiting may occur.</li> </ul> </td> </tr> <tr> <td>Midazolam</td> <td> <p>0.02 to <span class="nowrap_whitespace">0.03 mg/kg</span> over 2 to <span class="nowrap_whitespace">3 minutes</span></p> <p>Usual individual dose: 0.5 or <span class="nowrap_whitespace">1 mg</span> and titrated to effect</p> Maximum single dose: <span class="nowrap_whitespace">2.5 mg</span> <span class="nowrap_whitespace">(1.5 mg</span> in older adults) </td> <td>2 to 5</td> <td>30 to 60</td> <td>May repeat after 2 to <span class="nowrap_whitespace">5 minutes</span></td> <td> <ul> <li>Sedative and anxiolytic. No analgesia. Often combined with fentanyl for PSA.</li> <li>Useful as a single agent when minimal sedation (anxiolysis) is required.</li> <li>Relatively slow onset; requires more gradual initiation.</li> <li>Prolonged effect or delayed recovery in older adults and patients with impaired liver or kidney function. Use lower doses and longer dosing intervals.</li> <li>Use reduced dose in combination with other agents.</li> </ul> </td> </tr> <tr> <td>Fentanyl</td> <td>0.5 to <span class="nowrap_whitespace">1 mcg/kg</span></td> <td>2 to 3</td> <td>30 to 60</td> <td><span class="nowrap_whitespace">0.5 mcg/kg</span> every <span class="nowrap_whitespace">2 minutes</span> (usual maximum cumulative dose: <span class="nowrap_whitespace">5 mcg/kg</span> or approximately <span class="nowrap_whitespace">250 mcg)</span></td> <td> <ul> <li>Analgesic. No amnesia. Often combined with midazolam for PSA.</li> <li>Minimal hypotension and histamine release.</li> <li>Use reduced dose in combination with other agents (eg, maximum single dose: <span class="nowrap_whitespace">0.5 mcg/kg).</span></li> <li>May cause prolonged sedation in older adults or patients with impaired kidney or liver function; use lower doses (single and cumulative) and longer dosing intervals.</li> <li>Respiratory depression may occur.</li> </ul> </td> </tr> <tr> <td>Ketamine</td> <td>1 to <span class="nowrap_whitespace">2 mg/kg</span> over 1 to <span class="nowrap_whitespace">2 minutes</span></td> <td>0.5</td> <td>10 to 20</td> <td>0.25 to <span class="nowrap_whitespace">1 mg/kg</span> every 5 to <span class="nowrap_whitespace">10 minutes</span> (0.25 to <span class="nowrap_whitespace">0.5 mg/kg</span> if in combination with other sedatives)</td> <td> <ul> <li>Dissociative sedative, analgesic, and amnestic.</li> <li>Minimal cardiorespiratory depression; does not inhibit protective reflexes. Useful for patients at risk of hypotension or with potentially difficult airway.</li> <li>May be given intramuscularly; however, onset of sedation will be delayed by approximately <span class="nowrap_whitespace">5 minutes.</span></li> <li>Emergence reactions common in adults. Nausea and vomiting may occur.</li> <li>Sympathetic stimulation, tachycardia, and hypertension may also occur (rare).</li> </ul> </td> </tr> <tr> <td>Dexmedetomidine</td> <td> <p>Bolus: 0.5 to <span class="nowrap_whitespace">1 mcg/kg</span> over <span class="nowrap_whitespace">10 minutes</span></p> Infusion: 0.2 to <span class="nowrap_whitespace">1 mcg/kg/hour</span> </td> <td>5 to 10</td> <td>Post-continuous infusion: 60 to <span class="nowrap_whitespace">240 minutes</span> (dose dependent)</td> <td>Not applicable</td> <td> <ul> <li>Sedative. Some analgesia. Not amnestic.</li> <li>Useful in patients with potentially difficult airway or when tachycardia or hypertension would be particularly dangerous.</li> <li>May also be administered intranasally (2 to <span class="nowrap_whitespace">3 mcg/kg)</span> for anxiolysis and sedation when other routes are not optimal; however, onset of action is delayed.</li> <li>Impaired liver function: use lower starting doses.</li> <li>Decreased respiratory drive and airway obstruction can occur (rare).</li> <li>Bradycardia and hypotension can occur with loading doses and during rapid dose titration (dose dependent); however, hypertension with loading doses and high-dose infusion has also been observed.</li> </ul> </td> </tr> <tr> <td>Methohexital</td> <td>0.75 to <span class="nowrap_whitespace">1 mg/kg</span></td> <td>1</td> <td>10</td> <td><span class="nowrap_whitespace">0.5 mg/kg</span> every 2 to <span class="nowrap_whitespace">5 minutes</span></td> <td> <ul> <li>Sedative and amnestic. No analgesia.</li> <li>May cause prolonged sedation in older adults or patients with impaired kidney or liver function; use lower doses (single and cumulative) and longer dosing intervals.</li> <li>Cardiorespiratory depression, hypotension, and tachycardia can occur.</li> <li>Can precipitate or worsen seizures.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Older adults are at increased risk of adverse effects. Lower doses and less frequent administration are generally advised. Refer to UpToDate topic for discussion.</p>
For patients with obesity, dosing based on modifications of actual (total) body weight (eg, ideal body weight, lean body weight) may be preferred to avoid oversedation. Refer to UpToDate topic for discussion.</div><div class="graphic_footnotes">PSA: procedural sedation and analgesia.</div><div class="graphic_reference">Data from: Gan, TJ Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006;45(9):855-869. Falk, J, Zed, P, Etomidate for procedural sedation in the emergency department. Ann Pharmacother 2004;38:1272-7.</div><div id="graphicVersion">Graphic 52744 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
